Business Wire

DAI-NIPPON-PRINTING

31.8.2021 03:02:06 CEST | Business Wire | Press release

Share
DNP Develops Reflect Array to Expand 5G Coverage Area

Dai Nippon Printing Co., Ltd. (DNP, TOKYO: 7912) has developed a Reflect Array that flexibly reflects the millimetre waves used in fifth generation (5G) mobile communications systems to expand coverage area.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210830005245/en/

Compared to general metal reflectors, the new product is capable of reflecting millimetre waves in a more targeted manner. As a result, there are fewer restrictions on installation, making it possible to improve the communications environment in locations where radio waves have been difficult to reach, such as those in the shadow of buildings. In addition, the new product boasts superior design features allowing it to respond to various installation environment considerations.

Background

The 24GHz and above radio waves used in the high-speed large-capacity communications of 5G are higher frequency milliwaves than those used in 4G, and maintain a larger information capacity. At the same time, they are characterized by strong straightness properties and short reach, leading to radio waves being blocked in areas such as in the shadow of buildings making it difficult to ensure communication quality. Also, when adding base stations and relay equipment to resolve this issue, new challenges emerge, such as large costs and the difficulty of securing installation space.

DNP has once again risen to the challenge, taken advantage of proprietary microfabrication technology, and by applying an original concept has successfully separated the Frequency Selection Reflection Layer that selectively reflects predetermined frequency bands while merely passing through other radio waves, and the Reflective Direction Control Layer, a special dielectric layer that decides the direction of incoming and reflected radio waves, to develop a Reflect Array that makes it easier to control for the characteristics of each layer. The newly developed product is cheaper than installing base stations and relay equipment, and does not require a power source. It can, therefore, be installed in a variety of location, which contributes to significant improvements in the 5G communications environment.

Features

  • Can be installed in a variety of locations

Unlike metal reflectors that reflect radio waves directly as in a mirror, the newly developed product is a reflective array capable of the asymmetric reflection of specific frequency radio waves. It is possible to flexibly set the frequency band to be reflected, the incidence angle of the radio waves received from the base station, and the reflection angle to deliver the radio waves, along with the spread of the reflection waves. As a result, it is now possible to effectively deliver radio waves to locations where it was previously difficult to do so. As a power source is no longer needed the new product can also be used in locations where installation space is restricted.

  • Effective designs based on original concepts

The new product is comprised of three layers: the Frequency Selective Surface Layer that selectively reflects predetermined frequency bands while merely passing through other radio waves, the Reflective Direction Control Layer that decides the direction of incoming and reflected radio waves, and a Design Cover Layer that not only protects these two layers, but also provides the durability required of construction materials along with high level design features that are conducive to various installation environment considerations.

  • Effective improvement of radio wave conditions

We have made it is possible to pre-adjust the spread of the reflection waves in answer to the desire to deliver reflection waves over a broad area, or to gather those waves into specific devices.

  • Reduces the impact on existing radio waves

Unlike metal reflectors that reflect all radio waves, the new product passes through all but target radio waves, reducing the impact on existing radio waves.

  • Superior design features

It is possible to print various patterns on the surface of the Design Cover Layer, making it possible to add external designs, including interior, exterior and advertising signboards.

Usage Scene

Recently, we have seen more companies and organizations consider the adoption of 5G as a means of targeting the realization of smart cities and smart factories that exploit robots and the Internet of Things (IoT). Commercialization efforts are already underway. With the development of the Reflect Array, we anticipate the following installation instances in cases where the radio wave environment is expected to deteriorate due to obstacles, and aim to link these initiatives to the spread of 5G.

  • Improvement of the communication environment behind radio wave shields in smart factories
  • Improvement of mobile device usage environment indoors at business offices and educational sites
  • Usage at exhibition spaces where layouts change with each event and radio wave shielding conditions alter
  • Usage at stadiums and amusement facilities where area-specific information is delivered
  • Applications leveraging design elements, such as urban buildings, walls and signboards that require harmony with the surrounding environment

Looking Ahead

DNP will work jointly with various communications-related companies, including communications carriers, to verify the functionality of the new product, aiming for commercialization from FY 2023.

The new product is a Passive type Reflect Array that fixes the reflection direction of the radio waves. We will engage in joint development of an Active type Reflect Array with multiple companies, and this research has been selected as a national project in FY2021.

About DNP

DNP is one of the world’s largest comprehensive printing companies, providing a diverse portfolio of products and services to about 20,000 corporate clients worldwide. Since we were founded in 1876, we have consistently innovated new products and processes, and have successfully integrated proprietary printing and information technologies to branch out into various fields, including packaging, decorative materials, display components, and electronic devices. DNP continues to take on the challenge of new business fields, including those related to the environment, energy, and life sciences. Our aim is to become a principal provider of solutions to a variety of problems by developing and combining new technologies.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye